APLT
Applied Therapeutics, Inc.
Biotechnology
Market Cap$15M
5Y Perf.-99.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
APLT vs PTCT vs RARE vs SRPT
Revenue, margins, valuation, and 5-year total return — side by side.
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+48.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-64.8%
SRPT
Sarepta Therapeutics, Inc.
Biotechnology
Market Cap$2.18B
5Y Perf.-86.6%
APLT vs PTCT vs RARE vs SRPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | APLT | PTCT | RARE | SRPT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $15M | $5.35B | $2.57B | $2.18B |
| Revenue (TTM) | $1M | $827M | $669M | $2.18B |
| Net Income (TTM) | $-18M | $-187M | $-609M | $65M |
| Gross Margin | -28.5% | 49.7% | 83.6% | 34.4% |
| Operating Margin | -98.4% | -8.3% | -83.9% | -1.9% |
| Forward P/E | — | 8.3x | — | 5.9x |
| Total Debt | $3M | $492M | $1.28B | $1.04B |
| Cash & Equiv. | $79M | $985M | $434M | $801M |
APLT vs PTCT vs RARE vs SRPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
APLT
PTCT
RARE
SRPT
| Stock | May 20 | Feb 26 | Return |
|---|---|---|---|
| Applied Therapeutic… (APLT) | 100 | 0.2 | -99.8% |
| PTC Therapeutics, I… (PTCT) | 100 | 148.9 | +48.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 35.2 | -64.8% |
| Sarepta Therapeutic… (SRPT) | 100 | 13.4 | -86.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APLT vs PTCT vs RARE vs SRPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTCT and SRPT are tied at the top with 3 categories each — the right choice depends on your priorities. Sarepta Therapeutics, Inc. is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
APLT
Applied Therapeutics, Inc.
The Defensive Pick
APLT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 3.25, Low D/E 4.9%, current ratio 3.06x
Best for: sleep-well-at-night
PTCT
PTC Therapeutics, Inc.
The Income Pick
PTCT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.13
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs SRPT's 18.0%
- Beta 1.13, current ratio 2.35x
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
SRPT
Sarepta Therapeutics, Inc.
The Value Play
SRPT is the #2 pick in this set and the best alternative if value and quality is your priority.
- Better valuation composite
- 3.0% margin vs APLT's -18.1%
- 1.9% ROA vs APLT's -52.8%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs APLT's -95.4% |
| Value | SRPT | Better valuation composite |
| Quality / Margins | SRPT | 3.0% margin vs APLT's -18.1% |
| Stability / Safety | PTCT | Beta 1.13 vs APLT's 3.25 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PTCT | +58.2% vs APLT's -75.5% |
| Efficiency (ROA) | SRPT | 1.9% ROA vs APLT's -52.8% |
APLT vs PTCT vs RARE vs SRPT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2025
Segment breakdown not available.
APLT vs PTCT vs RARE vs SRPT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPTCTLAGGINGRARE
Who Leads Where
PTCT leads in 3 of 6 categories
SRPT leads 1 • APLT leads 0 • RARE leads 0 • 1 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
APLTApplied Therapeutics,…
0leads
SRPTSarepta Therapeutics,…
1leads
PTCTPTC Therapeutics, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs SRPTvs APLTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SRPT4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PTCT4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PTCT5/6
Risk & VolatilityBeta, volatility, and downside exposure
PTCT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SRPT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRPT is the larger business by revenue, generating $2.2B annually — 2184.2x APLT's $1M. SRPT is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to APLT's -18.1%. On growth, APLT holds the edge at +7.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $827M | $669M | $2.2B |
| EBITDAEarnings before interest/tax | -$98M | -$37M | -$536M | -$6M |
| Net IncomeAfter-tax profit | -$18M | -$187M | -$609M | $65M |
| Free Cash FlowCash after capex | -$87M | -$229M | -$487M | $107M |
| Gross MarginGross profit ÷ Revenue | -28.5% | +49.7% | +83.6% | +34.4% |
| Operating MarginEBIT ÷ Revenue | -98.4% | -8.3% | -83.9% | -1.9% |
| Net MarginNet income ÷ Revenue | -18.1% | -22.6% | -91.0% | +3.0% |
| FCF MarginFCF ÷ Revenue | -86.8% | -27.7% | -72.8% | +4.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.2% | -76.8% | -2.4% | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +72.9% | -100.3% | -17.2% | +162.6% |
SRPT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — APLT and RARE and SRPT each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Market CapShares × price | $15M | $5.3B | $2.6B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | -$62M | $4.9B | $3.4B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.14x | 8.29x | -4.48x | -2.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 5.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 5.42x | — | — |
| Price / SalesMarket cap ÷ Revenue | 32.67x | 3.09x | 3.82x | 0.99x |
| Price / BookPrice ÷ Book value/share | 0.25x | — | — | 1.91x |
| Price / FCFMarket cap ÷ FCF | — | 7.61x | — | — |
Evenly matched — APLT and RARE and SRPT each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
PTCT leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
SRPT delivers a 4.9% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-6 for RARE. APLT carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to SRPT's 0.91x. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs APLT's 3/9, reflecting strong financial health.
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.3% | — | -6.1% | +4.9% |
| ROA (TTM)Return on assets | -52.8% | -6.8% | -45.8% | +1.9% |
| ROICReturn on invested capital | — | — | -89.4% | -31.4% |
| ROCEReturn on capital employed | -4.8% | +55.9% | -46.4% | -24.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.05x | — | — | 0.91x |
| Net DebtTotal debt minus cash | -$77M | -$492M | $842M | $238M |
| Cash & Equiv.Liquid assets | $79M | $985M | $434M | $801M |
| Total DebtShort + long-term debt | $3M | $492M | $1.3B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | — | -1.67x | -14.49x | -14.00x |
PTCT leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PTCT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $16,026 today (with dividends reinvested), compared to $59 for APLT. Over the past 12 months, PTCT leads with a +58.2% total return vs APLT's -75.5%. The 3-year compound annual growth rate (CAGR) favors PTCT at 5.1% vs APLT's -60.8% — a key indicator of consistent wealth creation.
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | 0.0% | -16.0% | +10.7% | -2.4% |
| 1-Year ReturnPast 12 months | -75.5% | +58.2% | -21.8% | -43.4% |
| 3-Year ReturnCumulative with dividends | -94.0% | +16.1% | -44.5% | -83.6% |
| 5-Year ReturnCumulative with dividends | -99.4% | +60.3% | -77.2% | -72.1% |
| 10-Year ReturnCumulative with dividends | -98.9% | +733.2% | -59.4% | +18.0% |
| CAGR (3Y)Annualised 3-year return | -60.8% | +5.1% | -17.8% | -45.3% |
PTCT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PTCT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PTCT is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than APLT's 3.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PTCT currently trades 73.7% from its 52-week high vs APLT's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.11x | 1.03x | 1.36x | 1.95x |
| 52-Week HighHighest price in past year | $1.50 | $87.50 | $42.37 | $44.14 |
| 52-Week LowLowest price in past year | $0.09 | $37.94 | $18.29 | $10.42 |
| % of 52W HighCurrent price vs 52-week peak | +6.9% | +73.7% | +61.7% | +47.1% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 45.3 | 66.6 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 0 | 1.0M | 1.8M | 3.0M |
PTCT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PTCT as "Buy", RARE as "Buy", SRPT as "Buy". Consensus price targets imply 85.1% upside for RARE (target: $48) vs 21.6% for SRPT (target: $25).
| Metric | APLTApplied Therapeut… | PTCTPTC Therapeutics,… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $98.00 | $48.36 | $25.29 |
| # AnalystsCovering analysts | — | 26 | 33 | 54 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
PTCT leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SRPT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallPTC Therapeutics, Inc. (PTCT)Leads 3 of 6 categories
Loading custom metrics...
APLT vs PTCT vs RARE vs SRPT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is APLT or PTCT or RARE or SRPT a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus -95. 4% for Applied Therapeutics, Inc. (APLT). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate PTC Therapeutics, Inc. (PTCT) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — APLT or PTCT or RARE or SRPT?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +60. 3%, compared to -99. 4% for Applied Therapeutics, Inc. (APLT). Over 10 years, the gap is even starker: PTCT returned +852. 1% versus APLT's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — APLT or PTCT or RARE or SRPT?
By beta (market sensitivity over 5 years), PTC Therapeutics, Inc.
(PTCT) is the lower-risk stock at 1. 03β versus Applied Therapeutics, Inc. 's 3. 11β — meaning APLT is approximately 203% more volatile than PTCT relative to the S&P 500. On balance sheet safety, Applied Therapeutics, Inc. (APLT) carries a lower debt/equity ratio of 5% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — APLT or PTCT or RARE or SRPT?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus -95. 4% for Applied Therapeutics, Inc. (APLT). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — APLT or PTCT or RARE or SRPT?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -232. 1% for Applied Therapeutics, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -229. 2% for APLT. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is APLT or PTCT or RARE or SRPT more undervalued right now?
Analyst consensus price targets imply the most upside for RARE: 85.
1% to $48. 36.
07Which pays a better dividend — APLT or PTCT or RARE or SRPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is APLT or PTCT or RARE or SRPT better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc.
(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +852. 1% 10Y return). Applied Therapeutics, Inc. (APLT) carries a higher beta of 3. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +852. 1%, APLT: -98. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between APLT and PTCT and RARE and SRPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: APLT is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock; RARE is a small-cap high-growth stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(APLT: 719.7% · PTCT: -76.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.